Evidence map›Paper›PMID 39040540›Full record

ArticleBiochemistry and biophysics reports2024

Combinative workflow for mRNA vaccine development.

Renuka Khanzode, Garima Soni, Shalini Srivastava, Sharad Pawar, Rucha Wadapurkar, Ajay Singh

Abstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Renuka KhanzodeGennova Biopharmaceuticals Ltd, ITBT Park, Rajiv Gandhi Infotech Park, Hinjawadi, Phase-2, Pune, Maharashtra, 411057, India.
Garima SoniGennova Biopharmaceuticals Ltd, ITBT Park, Rajiv Gandhi Infotech Park, Hinjawadi, Phase-2, Pune, Maharashtra, 411057, India.
Shalini SrivastavaGennova Biopharmaceuticals Ltd, ITBT Park, Rajiv Gandhi Infotech Park, Hinjawadi, Phase-2, Pune, Maharashtra, 411057, India.
Sharad PawarGennova Biopharmaceuticals Ltd, ITBT Park, Rajiv Gandhi Infotech Park, Hinjawadi, Phase-2, Pune, Maharashtra, 411057, India.
Rucha WadapurkarGennova Biopharmaceuticals Ltd, ITBT Park, Rajiv Gandhi Infotech Park, Hinjawadi, Phase-2, Pune, Maharashtra, 411057, India.
Ajay SinghGennova Biopharmaceuticals Ltd, ITBT Park, Rajiv Gandhi Infotech Park, Hinjawadi, Phase-2, Pune, Maharashtra, 411057, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, mRNA has gained a lot of attention in the field of vaccines, gene therapy, and protein replacement therapies. Herein, we are demonstrating a comprehensive approach to designing, cloning, and characterizing an antigenic cassette for the development of mRNA vaccine for COVID-19. The gene encoding the antigenic spike protein of the SARS-CoV-2 Omicron variant (B.1.1.529) was designed using the databases, characterized by

Indexed as

mRNAOmicronSARS-CoV-2SOE-PCRVaccine

Identifiers

PMID39040540
PMCPMC11261026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.